Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

Mun Yee Koh, Tae-Hoon Chung, Nicole Xin Ning Tang, Sabrina Hui Min Toh, Jianbiao Zhou, Tze King Tan, Leilei Chen, Wee Joo Chng, Phaik Ju Teoh

Blood blood.2024024429.

https://doi.org/10.1182/blood.2024024429

Published: 2024

Includes: Supplemental data

Journal Articles

The c-MAF/SLP76 Axis Modulates Immune Evasion and Drives Malignancy in Multiple Myeloma Via Epigenetic Reprogramming

Zhenfeng Dai, Yunlu Jia, Jianbiao Zhou, Wee-Joo Chng, Zhen Cai

Blood (2024) 144 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2024-206958

Published: 2024

Journal Articles

Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma

Sinan Xiong, Jianbiao Zhou, Tze King Tan, Sabrina Hui-Min Toh, Kalpnaa Balan, Yunlu Jia, Tae-Hoon Chung, Takaomi Sanda, Wee Joo Chng

Blood (2021) 138 (Supplement 1): 2209.

https://doi.org/10.1182/blood-2021-149006

Published: 2021

Journal Articles

Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia

Jianbiao Zhou, Jonathan Adam Scolnick, Stacy Xu, Melissa Ooi, Priscella Shirley Chia, Sabrina Hui-Min Toh, Kalpnaa Balan, Michael Lovci, Tuan Zea Tan, Jen Wei Ying, Chin-Hin NG, Wee-Joo Chng

Blood (2021) 138 (Supplement 1): 378.

https://doi.org/10.1182/blood-2021-149022

Published: 2021

Journal Articles

Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma

Jianbiao Zhou, MDPhD, Sabrina Hui Min Toh, BSc, Kalpnaa Balan, BSc, Tze King Tan, PhD, Yunlu Jia, MD, Jing Quan Lim, PhD, Choon Kiat Ong, PhDBSc, Soon Thye Lim, MBBS, MRCP, Tuan Zea Tan, Siok-Bian Ng, Takaomi Sanda, MD PhD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-136244

Published: 2020

Journal Articles

Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma

Jianbiao Zhou, MD PhD, Yunlu Jia, MD, Tze King Tan, PhD, Tae-Hoon Chung, PhD, Takaomi Sanda, MD PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2019) 134 (Supplement_1): 362.

https://doi.org/10.1182/blood-2019-124252

Published: 2019

Journal Articles

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Jianbiao Zhou, MD,PhD, Jessie Yiying Quah, B.S., Jing Yuan Chooi, BSc, Sabrina Hui-Min Toh, B.S., Yvonne Ng, B.S., Baohong Lin, B.S., Motomi Osato, MD, PhD, Qihui Seet, B.S., PhD, A.G. Lisa Ooi, B.S., PhD, Bertil Lindmark, MD PhD, Mark McHale, B.S., PhD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS

Blood (2018) 132 (Supplement 1): 4047.

https://doi.org/10.1182/blood-2018-99-114392

Published: 2018

Journal Articles

Plasma HCK Level As a Biomarker Predicting Poor Outcome in Acute Myeloid Leukemia

Pak Ling Lui, MBBS, Elaine Seah, BSc, Jianbiao Zhou, MD PhD, Baohong Lin, BSc, Wee Joo Chng, MB ChB, MRCP, PhD, Chin Hin Ng, MD MRCP

Blood (2017) 130 (Supplement 1): 3862.

https://doi.org/10.1182/blood.V130.Suppl_1.3862.3862

Published: 2017

Journal Articles

Plasma LRG1 Protein Are Overexpressed in Acute Myeloid Leukemia with High Sensitivity and High Specificity in Differentiating Leukemic Plasma from Normal Plasma — a Potential Biomarker for Minimal Residual Disease Detection

Chin Hin Ng, MD MRCP, Xu Liang, PhD, Jianbiao Zhou, MD PhD, Elaine Seah, BSc, Baohong Lin, BSc, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Yoon-Pin Lim, BSc, PhD

Blood (2017) 130 (Supplement 1): 5083.

https://doi.org/10.1182/blood.V130.Suppl_1.5083.5083

Published: 2017

Journal Articles

HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML

Jerome Boyd-Kirkup, PhD, Dipti Thakkar, PhD, Peter Brauer, PhD, Jianbiao Zhou, MD PhD, Wee-Joo Chng, MBBS, PhD FRCPath, FRCP, Piers Jamie Ingram, PhD MBA

Blood (2017) 130 (Supplement 1): 1378.

https://doi.org/10.1182/blood.V130.Suppl_1.1378.1378

Published: 2017

Journal Articles

The Pro-Metastasis Tyrosine Phosphatase, PRL-3 ( PTP4A3 ), Is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia

Jianbiao Zhou, M.D., Ph.D., Lip-Lee Cheong, B.sc., Sylvia Mahara, B.sc., Shaw-Cheng Liu, B.sc., Phyllis SY Chong, B.sc., Chonglei Bi, B.sc., Tze-Loong Koh, B.sc., Kelly OK Ong, B.sc., Qi Zeng, Ph.D., Wee-Joo Chng, MRCP, MRCPath

Blood (2011) 118 (21): 2741.

https://doi.org/10.1182/blood.V118.21.2741.2741

Published: 2011

Journal Articles

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

Jianbiao Zhou, Chonglei Bi, Lip-Lee Cheong, Sylvia Mahara, Shaw-Cheng Liu, Kian-Ghee Tay, Tze-Loong Koh, Qiang Yu, Wee-Joo Chng

Blood (2011) 118 (10): 2830–2839.

https://doi.org/10.1182/blood-2010-07-294827

Published: 2011

Includes: Supplemental data

Journal Articles

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Jianbiao Zhou, M.D., Ph.D., Chonglei Bi, B.sc., Shaw-Cheng Liu, Kian-Ghee Tay, Lip-Lee Cheong, B.sc., Tze-Loong Koh, B.sc., Qiang Yu, Ph.D., Wee-Joo Chng, MRCP, MRCPath

Blood (2010) 116 (21): 4355.

https://doi.org/10.1182/blood.V116.21.4355.4355

Published: 2010

Journal Articles

Gene Expression Profiling Reveals Activation of Multiple Oncogenic Pathways and Over-Expression of Survivin in the Pathogenesis of Extranodal Nasal-Type NK/T Cell Lymphoma.

Wee-Joo Chng, Viknesvaran Selvarajan, Gaofeng Huang, Jianbiao Zhou, MD, MS, Mark Law, Andrew L Feldman, MD, Salto-Tellez Manual, Siok-Bian Ng

Blood (2009) 114 (22): 3931.

https://doi.org/10.1182/blood.V114.22.3931.3931

Published: 2009

Journal Articles

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Jianbiao Zhou, Chonglei Bi, Jasinghe V. Janakakumara, Shaw-Cheng Liu, Wee-Joo Chng, Kian-Ghee Tay, Lai-Fong Poon, Zhigang Xie, Senthilnathan Palaniyandi, Hanry Yu, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen

Blood (2009) 113 (17): 4052–4062.

https://doi.org/10.1182/blood-2008-05-156422

Published: 2009

Includes: Supplemental data

Journal Articles

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Jianbiao Zhou, MD, MS, Chonglei Bi, Bsc, Shaw-Cheng Liu, Wee-Joo Chng, MD, Kian-Ghee Tay, Bsc, Hanry Yu, Ph.D., Keith Glaser, Ph.D., Daniel Albert, PhD, BSc, Steven K Davidsen, Ph.D., Chien-Shing Chen, MD, PhD

Blood (2008) 112 (11): 1618.

https://doi.org/10.1182/blood.V112.11.1618.1618

Published: 2008

Journal Articles

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Jianbiao Zhou, MD, MSc, Chonglei Bi, B.S., Lai Fong Poon, B.S., Viraj J. Janakakumara, B.S., Jiaying Khng, Hanry Yu, Ph.D., Keith B. Glaser, Ph.D., Daniel H. Albert, Ph.D., Davidsen K. Davidsen, Ph.D., Chien-Shing Chen, Ph.D.

Blood (2007) 110 (11): 2367.

https://doi.org/10.1182/blood.V110.11.2367.2367

Published: 2007

Journal Articles

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01

Jianbiao Zhou, Meredith A Goldwasser, Aihong Li, Suzanne E. Dahlberg, Donna Neuberg, Hongjun Wang, Virginia Dalton, Kathryn D McBride, Stephen E. Sallan, Lewis B Silverman, John G. Gribben

Blood (2007) 110 (5): 1607–1611.

https://doi.org/10.1182/blood-2006-09-045369

Published: 2007

Includes: Supplemental data

Journal Articles

Molecular Analysis of T-Cell Receptor Gene Rearrangements in Children with T-Cell Acute Lymphoblast Leukemia on DFCI ALL Consortium Protocol 95-01.

Aihong Li, MD PhD, Jianbiao Zhou, MD MSc, Hongjun Wang, BS, Meredith A. Goldwasser, ScD, Cheryl Lyons, BA, Stephen E. Sallan, MD, Lewis B. Silverman, MD, John G. Gribben, MD DSc

Blood (2004) 104 (11): 1084.

https://doi.org/10.1182/blood.V104.11.1084.1084

Published: 2004

Journal Articles

Distinct VDJ-H Gene Usage between Mutated and Unmutated Patients in B-CLL: Implications for Pathogenesis and Correlation with Clinical Outcome.

Katja Mauerer, MD, David Zahrieh, MSc, Gullu Gorgun, PhD, Aihong Li, MD PhD, Jianbiao Zhou, MD MSc, Laura Rassenti, PhD, John G. Gribben, MD DSc

Blood (2004) 104 (11): 970.

https://doi.org/10.1182/blood.V104.11.970.970

Published: 2004

NARROW

ADAR1-regulated cytoplasmic dsRNA-sensing pathway is a novel mechanism of lenalidomide resistance in multiple myeloma

The c-MAF/SLP76 Axis Modulates Immune Evasion and Drives Malignancy in Multiple Myeloma Via Epigenetic Reprogramming

Super-Enhancer-Driven PPP1R15B As an Oncogenic and Potential Therapeutic Target in Multiple Myeloma

Single-Cell Multi-Omic Analysis Uncovers Comprised Immune Function and Primary Resistance Mechanism in Acute Myeloid Leukemia

Super-Enhancer-Driven TOX2 Mediates Oncogenesis in Natural Killer/T Cell Lymphoma

Super-Enhancer Profiling Identifies Novel Oncogenes and Therapeutic Targets in Multiple Myeloma

ASLAN003, a Novel and Potent Dihydroorotate Dehydrogenase (DHODH) Inhibitor, Induces Differentiation of Acute Myeloid Leukemia

Plasma HCK Level As a Biomarker Predicting Poor Outcome in Acute Myeloid Leukemia

Plasma LRG1 Protein Are Overexpressed in Acute Myeloid Leukemia with High Sensitivity and High Specificity in Differentiating Leukemic Plasma from Normal Plasma — a Potential Biomarker for Minimal Residual Disease Detection

HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML

The Pro-Metastasis Tyrosine Phosphatase, PRL-3 ( PTP4A3 ), Is a Novel Target of BCR-ABL Signaling Involved in Human Chronic Myeloid Leukemia

The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML

The Histone Methyltransferase Inhibitor, DZNep, Upregulates TXNIP, Increases ROS Production and Targets Leukemia Cells In AML

Gene Expression Profiling Reveals Activation of Multiple Oncogenic Pathways and Over-Expression of Survivin in the Pathogenesis of Extranodal Nasal-Type NK/T Cell Lymphoma.

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML

Identification of Core Gene Signature Associated with Synergism Between ABT-869, a FLT3 Inhibitor and SAHA, a HDAC Inhibitor in AML with FLT3-ITD Mutation.

Overactivation of STAT Pathways and Overexpression of Survivin Confer Resistance to FLT3 Inhibitors and Could Be Therapeutic Targets in AML.

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01

Molecular Analysis of T-Cell Receptor Gene Rearrangements in Children with T-Cell Acute Lymphoblast Leukemia on DFCI ALL Consortium Protocol 95-01.

Distinct VDJ-H Gene Usage between Mutated and Unmutated Patients in B-CLL: Implications for Pathogenesis and Correlation with Clinical Outcome.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only